Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies

by Nayar, Utthara, Cohen, Ofir, Kapstad, Christian, Cuoco, Michael S., Waks, Adrienne G., Wander, Seth A., Painter, Corrie, Freeman, Samuel, Persky, Nicole S., Marini, Lori, Helvie, Karla, Oliver, Nelly, Rozenblatt-Rosen, Orit, Ma, Cynthia X., Regev, Aviv, Winer, Eric P., Lin, Nancy U., Wagle, Nikhil
Published 2020